In its continued effort to bring ultrasound contrast agent Definity to market, DuPont Pharmaceuticals has filed a marketing authorization application (MAA) for the agent with the European Medicines Evaluation Agency (EMEA). The application is based on
In its continued effort to bring ultrasound contrast agent Definity to market, DuPont Pharmaceuticals has filed a marketing authorization application (MAA) for the agent with the European Medicines Evaluation Agency (EMEA). The application is based on seven multicenter phase III clinical trials that included 610 patients at 52 U.S. medical centers and covers the use of Definity for contrast-enhanced ultrasound imaging of the heart and abdomen.
EMEAs review arm, the Committee for Proprietary Medicinal Products (CPMP), will examine the North Billerica, MA, companys application. If cleared by the CPMP, DuPont will be able to sell Definity in all of the European Union countries. DuPont has also filed a new drug submission (NDS) for Definity with the Health Protection Branch of Health Canada, and, in 1998, filed an NDA with the Food and Drug Administration (SCAN 12/16/98).
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.